Press Releases.

VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update

VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update

VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common Stock

VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation

Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar

Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network

Volition Issues Business Review 2022

VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update

Volition Announces Clinical Research Study with Oncovet

Volition to Participate in a Lung Cancer Screening Study in France